Switching from deuruxolitinib to baricitinib in alopecia areata: a real-world cohort of 36 patients.

Published: 30 June 2026| Version 2 | DOI: 10.17632/sgg3nc832f.2
Contributor:
Juan Jiménez-Cauhé

Description

Supplemental Table 1. Response status at different timepoints before and after switching from deuruxolitinib to baricitinib.

Files

Categories

Hair Disorder, Alopecia Areata

Licence